Generation Bio Co. (NASDAQ:GBIO) just released its third-quarter report and things are looking bullish. Results clearly exceeded expectations, with a substantial revenue beat leading to smaller losses in what looks like a definite win for investors. Revenues were US$7.6m and the statutory loss per share was US$0.23, smaller than the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Generation Bio after the latest results.

See our latest analysis for Generation Bio

Following the recent earnings report, the consensus from seven analysts covering Generation Bio is for revenues of US$6.55m in 2025. This implies a stressful 65% decline in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 50% to US$1.08. Before this latest report, the consensus had been expecting revenues of US$6.50m and US$1.04 per share in losses. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a pronounced increase to its losses per share forecasts.

The consensus price target held steady at US$7.50, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Generation Bio analyst has a price target of US$10.00 per share, while the most pessimistic values it at US$5.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that revenue is expected to reverse, with a forecast 57% annualised decline to the end of 2025. That is a notable change from historical growth of 99% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Generation Bio is expected to lag the wider industry.